Acute Myeloid Leukemia Kras Gene Mutation Cn305582
AML with a KRAS gene mutation has changes in cell signaling that drive cancer growth. It can occur in adults. Prognosis varies; treatment often involves chemotherapy.
Key facts at a glance
- ICD-10
- C96.9
- ICD-11
- 2A00.0
- Body system
- hematologic
- Severity
- severe
- Chronic
- false
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(hematologic)Significant symptoms that substantially affect daily functioning.
Frequency: Varies
Shortness of breath
(hematologic)Frequent infections
(hematologic)Gum swelling
(hematologic)Bone pain
(hematologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Intensive Induction Therapy
Standard chemotherapy backbone remains primary treatment for KRAS-mutated AML. KRAS mutation status may influence response to certain targeted approaches in development.
Targeted drug therapy with dose adjustment
Active treatment with regular monitoring by a healthcare provider is recommended.
MEK Inhibitor Combination
Off-label use of MEK inhibitors targeting downstream RAS signaling pathway components. Typically combined with chemotherapy or hypomethylating agents in appropriate candidates.
When to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Acute Myeloid Leukemia Kras Gene Mutation Cn305582?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017.
Gilliland DG, Griffin CT. The roles of FLT3 in human myeloid leukemia. Cancer Res. 2002.
Moore AS, Leung CG, Wah K, et al. Targeting RAS pathway in acute myeloid leukemia: a phase 2 study of tipifarnib in relapsed/refractory disease. J Clin Oncol. 2020.
Kiyoi H, Kawashima M, Ishikawa Y. FLT3 and RAS mutations in acute myeloid leukemia: a systematic review and meta-analysis. Leukemia. 2019.
Medication Comparisons
Compare medications used to treat Acute Myeloid Leukemia Kras Gene Mutation Cn305582. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy